

DISCLOSURE TEMPLATE - Menarini Stemline N.V./S.A.

Art. 36 ter. 3

Date of publication: 06/2026

Full name Art. 36 bis	HCPs: City of Principal Practice HCOs: city where registered Art. 36. quater	Country of Principal Practice Art. 36 bis2	Principal Practice Address Art. 36 quater	Unique country identifier OPTIONAL Art. 36 quater	Donations and grants Art. 36 quater 2 I a	Contributions to expenses related to scientific events (Art. 36 quater 2Ib & 36 quater 2 II a)			Fees for services & consultancy quater 2 I c & 36 quater 2 II b)		TOTAL OPTIONAL
						Sponsorship agreements with HCOs / third parties appointed by HCOs to manage a scientific event	Registration fees	Travel and accommodation expenses	Fees	Related expenses agreed in the fee for service or consultancy agreement, including travel & accommodation relevant to the contract	

HCP	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (all transfers of value during a year for an individual HCP will be summed up – Itemization should be available for the individual recipient or public authorities' consultation only, as appropriate)												
						NA	NA						
						NA	NA						
						NA	NA						
	OTHERS, NOT INCLUDED ABOVE - Where information cannot be disclosed on an individual basis for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients (Art. 36 quater 3)					NA	NA							
Number of beneficiaries in aggregate disclosure (Art. 36 quater 3)					NA	NA							
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed (Art. 36 quater 3)					NA	NA	%	%	%	%			

HCO	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (all transfers of value during a year for an individual HCO will be summed up – Itemization should be available for the individual recipient or public authorities' consultation only, as appropriate)												
	Pharmaconsult Sarl	LUXEMBOURG	3348 LEUDELANGE	RUE DES CHAMPS 21	B153654		€	3.000,00					€ 3.000,00
	OTHERS, NOT INCLUDED ABOVE - Where information cannot be disclosed on an individual basis for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients (Art. 36 quater 3)													
Number of beneficiaries in aggregate disclosure (Art. 36 quater 3)													
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed (Art. 36 quater 3)					%	%	%	%	%	%			

R&D	AGGREGATED DISCLOSURE											
	Transfers of value related to research and development as defined in Article 36 quater 5											TOTAL AMOUNT

PO	INDIVIDUAL NAMED DISCLOSURE - one line per PO (all transfers of value during a year for an individual PO will be summed up – Itemization should be available for the individual recipient or public authorities' consultation only, as appropriate)												
	OTHERS, NOT INCLUDED ABOVE - Where information cannot be disclosed on an individual basis for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients (Art. 36 quater 3)													
Number of beneficiaries in aggregate disclosure (Art. 36 quater 3)													
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed (Art. 36 quater 3)					%	%	%	%	%	%			